{"id":"vancomycin-injection","_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Vancomycin Injection","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:16:10.943270+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:16:26.728057+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:16:18.362347+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vancomycin Injection","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:16:19.192614+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108760/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:16:20.189289+00:00"}},"_dailymed":null,"aiSummary":"Vancomycin Injection, marketed by Murdoch Childrens Research Institute, is a well-established antibiotic in the healthcare sector. The key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. The primary risk lies in the potential increase in competition post-patent expiry, which could impact market share and financial performance.","_scrapedAt":"2026-03-27T23:39:21.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:16:26.728625+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07495150","phase":"NA","title":"Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis","status":"NOT_YET_RECRUITING","sponsor":"yilong Wang","startDate":"2026-04-01","conditions":"Blood-Brain Barrier, Bacterial Meningitis","enrollment":86},{"nctId":"NCT06748144","phase":"PHASE2, PHASE3","title":"IO Vancomycin Spine","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-05","conditions":"Lumbar Fusion Surgery","enrollment":30},{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT07300553","phase":"PHASE2","title":"Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-02","conditions":"IBD, Crohn Disease, Ulcerative Colitis (UC)","enrollment":45},{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT06637332","phase":"PHASE4","title":"Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2024-11-14","conditions":"Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia","enrollment":300},{"nctId":"NCT05571722","phase":"PHASE4","title":"Linezolid or Vancomycin Surgical Site Infection Prophylaxis","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-11-12","conditions":"Antibiotic Prophylaxis, General Surgery","enrollment":1160},{"nctId":"NCT07267013","phase":"PHASE2","title":"Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC)","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-03-30","conditions":"Aortic Surgery, Extracorporeal Circulation","enrollment":25},{"nctId":"NCT07283068","phase":"NA","title":"IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02-15","conditions":"Revision Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT07282782","phase":"PHASE4","title":"A Prospective, Randomized Parallel Group Study of the Efficacy of Vancomycin Administered Through Intraarticular Injection Versus Intraosseous Injection Versus Intravenous Infusion in Patients Undergoing Total Knee Arthroplasty","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-06-10","conditions":"Total Knee Arthroplasty","enrollment":30},{"nctId":"NCT05766670","phase":"PHASE3","title":"Intramedullary Calcium Sulfate Antibiotic Depot","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-04-08","conditions":"Open tíbia Fracture, Osteomyelitis Tibia, Tibial Fractures","enrollment":497},{"nctId":"NCT02284126","phase":"PHASE3","title":"Topical Vancomycin for Neurosurgery Wound Prophylaxis","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-10","conditions":"Infection, Surgery, Nervous System Diseases","enrollment":1103},{"nctId":"NCT05831774","phase":"PHASE4","title":"IO Vancomycin in TSA","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-06-01","conditions":"Shoulder Injuries","enrollment":33},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT06640491","phase":"PHASE1, PHASE2","title":"Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-15","conditions":"Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT06384651","phase":"PHASE4","title":"Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-03","conditions":"Infections, Ankle Arthritis","enrollment":40},{"nctId":"NCT06166381","phase":"NA","title":"Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL Reconstruction","status":"RECRUITING","sponsor":"University of Duhok","startDate":"2024-01-25","conditions":"Infection, Bacterial","enrollment":288},{"nctId":"NCT05502380","phase":"PHASE3","title":"Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery","status":"RECRUITING","sponsor":"Balgrist University Hospital","startDate":"2022-09-15","conditions":"Surgical Site Infection, Microbial Colonization, Antibiotic Resistant Infection","enrollment":1100},{"nctId":"NCT04192994","phase":"NA","title":"Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2019-01-01","conditions":"Endophthalmitis","enrollment":25},{"nctId":"NCT06084754","phase":"NA","title":"Effect of Pulsed Electromagnetic Field Stimulation on Localized Pediatric Osteomyelitis","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-11-27","conditions":"Osteomyelitis","enrollment":20},{"nctId":"NCT04035369","phase":"NA","title":"Endophthalmitis Post Intravitreal Injections","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-03-01","conditions":"Endophthalmitis","enrollment":310},{"nctId":"NCT05705843","phase":"PHASE4","title":"IO vs IV Vancomycin in Tourniquetless TKA","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-25","conditions":"Infection, Surgical Site","enrollment":40},{"nctId":"NCT04673877","phase":"PHASE1","title":"Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-08-26","conditions":"Infection, Hand Injury Wrist, Hand Injuries","enrollment":20},{"nctId":"NCT02590523","phase":"PHASE3","title":"Intracameral Antibiotic Safety Study","status":"SUSPENDED","sponsor":"Panhandle Eye Group, LLP","startDate":"2023-01","conditions":"Intracameral Antibiotics, Cataract Surgery, Phacoemulsification","enrollment":500},{"nctId":"NCT03506347","phase":"PHASE2, PHASE3","title":"Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-09-24","conditions":"Arthropathy of Knee Joint","enrollment":24},{"nctId":"NCT00915967","phase":"NA","title":"Prevention of Neurosurgical Wound Infections","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2009-05-13","conditions":"Surgical Wound Infections","enrollment":214},{"nctId":"NCT00695903","phase":"PHASE2","title":"Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-09-17","conditions":"Endocarditis, Bacterial, Infective Endocarditis","enrollment":38},{"nctId":"NCT00711802","phase":"PHASE4","title":"Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-07-23","conditions":"Skin Diseases, Infectious","enrollment":396},{"nctId":"NCT02515045","phase":"PHASE4","title":"Dropless vs. Standard Drops Contralateral Eye Study","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2015-01","conditions":"Cataract","enrollment":59},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43},{"nctId":"NCT00295178","phase":"PHASE4","title":"Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-02-20","conditions":"Cellulitis","enrollment":80},{"nctId":"NCT02538211","phase":"NA","title":"The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-09","conditions":"Rotavirus Infections, Intestinal Bacteria Flora Disturbance, Reaction - Vaccine Nos","enrollment":63},{"nctId":"NCT02104934","phase":"NA","title":"A Randomised Controlled Trial Comparing Single Shot Adductor Canal Block With Local Infiltration Analgesia for Postoperative Analgesia After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Changi General Hospital","startDate":"2014-03","conditions":"Analgesia in Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT00424190","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-02","conditions":"Bacterial Infections","enrollment":698},{"nctId":"NCT00423657","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-03","conditions":"Bacterial Infections","enrollment":680},{"nctId":"NCT02411331","phase":"NA","title":"Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2015-03","conditions":"Lock Solution, Catheter Related Blood Stream Infections, Central Venous Catheter Infection","enrollment":180},{"nctId":"NCT00925093","phase":"PHASE1","title":"Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection","status":"WITHDRAWN","sponsor":"Aarhus University Hospital","startDate":"2011-09","conditions":"Neurosurgery","enrollment":""},{"nctId":"NCT01019681","phase":"PHASE1","title":"Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia","status":"TERMINATED","sponsor":"Richard Burt, MD","startDate":"2009-11","conditions":"Critical Limb Ischemia","enrollment":1}],"_emaApprovals":[],"_faersSignals":[{"count":411,"reaction":"DEATH"},{"count":175,"reaction":"ACUTE KIDNEY INJURY"},{"count":139,"reaction":"TREATMENT FAILURE"},{"count":103,"reaction":"NEPHROPATHY TOXIC"},{"count":92,"reaction":"RENAL FAILURE ACUTE"},{"count":37,"reaction":"DRUG INEFFECTIVE"},{"count":34,"reaction":"DRUG INTERACTION"},{"count":34,"reaction":"LINEAR IGA DISEASE"},{"count":18,"reaction":"INFECTION"},{"count":17,"reaction":"DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS"}],"crossReferences":{"chemblId":"CHEMBL2108760"},"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Firvanq","vancomycin","placebo","Vancocin","Vancocin Placebo"],"phase":"marketed","status":"active","brandName":"Vancomycin Injection","genericName":"Vancomycin Injection","companyName":"Murdoch Childrens Research Institute","companyId":"murdoch-childrens-research-institute","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:16:26.728625+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}